156 related articles for article (PubMed ID: 37142293)
1. Risk of malignant lymphomas in patients with inflammatory bowel disease: a population-based cohort study.
Yu J; Refsum E; Wieszczy P; Helsingen LM; Perrin V; Högdén A; Løberg M; Blom J; Bretthauer M; Adami HO; Ye W; Kalager M
BMJ Open Gastroenterol; 2023 May; 10(1):. PubMed ID: 37142293
[TBL] [Abstract][Full Text] [Related]
2. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
3. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.
Dulai PS; Thompson KD; Blunt HB; Dubinsky MC; Siegel CA
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1443-51; quiz e88-9. PubMed ID: 24462626
[TBL] [Abstract][Full Text] [Related]
4. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
Kotlyar DS; Lewis JD; Beaugerie L; Tierney A; Brensinger CM; Gisbert JP; Loftus EV; Peyrin-Biroulet L; Blonski WC; Van Domselaar M; Chaparro M; Sandilya S; Bewtra M; Beigel F; Biancone L; Lichtenstein GR
Clin Gastroenterol Hepatol; 2015 May; 13(5):847-58.e4; quiz e48-50. PubMed ID: 24879926
[TBL] [Abstract][Full Text] [Related]
5. Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
Cheddani H; Dauchet L; Fumery M; Charpentier C; Marie Bouvier A; Dupas JL; Pariente B; Peyrin-Biroulet L; Savoye G; Gower-Rousseau C
Am J Gastroenterol; 2016 Oct; 111(10):1428-1436. PubMed ID: 27481308
[TBL] [Abstract][Full Text] [Related]
6. Risk of hepato-pancreato-biliary cancer is increased by primary sclerosing cholangitis in patients with inflammatory bowel disease: A population-based cohort study.
Yu J; Refsum E; Helsingen LM; Folseraas T; Ploner A; Wieszczy P; Barua I; Jodal HC; Melum E; Løberg M; Blom J; Bretthauer M; Adami HO; Kalager M; Ye W
United European Gastroenterol J; 2022 Mar; 10(2):212-224. PubMed ID: 35107865
[TBL] [Abstract][Full Text] [Related]
7. Risk of Cancer in Paediatric onset Inflammatory Bowel Diseases: A Nation-wide Study From the epi-IIRN.
Atia O; Harel S; Ledderman N; Greenfeld S; Kariv R; Dotan I; Balicer R; Silverman B; Matz E; Levi Z; Waterman M; Fried I; Rowe JM; Turner D
J Crohns Colitis; 2022 Jun; 16(5):786-795. PubMed ID: 34791097
[TBL] [Abstract][Full Text] [Related]
8. Impact of thiopurines and tumour necrosis factor antagonists on primary sclerosing cholangitis outcomes in patients with inflammatory bowel disease.
Biron A; Beaugerie L; Chazouillères O; Kirchgesner J
Aliment Pharmacol Ther; 2022 Sep; 56(5):857-868. PubMed ID: 35789494
[TBL] [Abstract][Full Text] [Related]
9. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.
Siegel CA; Marden SM; Persing SM; Larson RJ; Sands BE
Clin Gastroenterol Hepatol; 2009 Aug; 7(8):874-81. PubMed ID: 19558997
[TBL] [Abstract][Full Text] [Related]
10. Risk of haematopoietic cancer in patients with inflammatory bowel disease.
Askling J; Brandt L; Lapidus A; Karlén P; Björkholm M; Löfberg R; Ekbom A
Gut; 2005 May; 54(5):617-22. PubMed ID: 15831904
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory bowel disease and risk of adenocarcinoma and neuroendocrine tumors in the small bowel.
Yu J; Refsum E; Perrin V; Helsingen LM; Wieszczy P; Løberg M; Bretthauer M; Adami HO; Ye W; Blom J; Kalager M
Ann Oncol; 2022 Jun; 33(6):649-656. PubMed ID: 35276334
[TBL] [Abstract][Full Text] [Related]
12. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
13. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease.
Chupin A; Perduca V; Meyer A; Bellanger C; Carbonnel F; Dong C
Aliment Pharmacol Ther; 2020 Oct; 52(8):1289-1297. PubMed ID: 32840893
[TBL] [Abstract][Full Text] [Related]
14. Cancer risk in patients with inflammatory bowel disease: a population-based study.
Bernstein CN; Blanchard JF; Kliewer E; Wajda A
Cancer; 2001 Feb; 91(4):854-62. PubMed ID: 11241255
[TBL] [Abstract][Full Text] [Related]
15. Lack of Increased Risk of Lymphoma with Thiopurine Therapy Regardless of Dose and Duration of Treatment in Japanese Patients with Inflammatory Bowel Diseases.
Kobayashi T; Udagawa E; Hibi T
Digestion; 2022; 103(2):169-173. PubMed ID: 34983046
[TBL] [Abstract][Full Text] [Related]
16. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
Bae JM; Lee HH; Lee BI; Lee KM; Eun SH; Cho ML; Kim JS; Park JM; Cho YS; Lee IS; Kim SW; Choi H; Choi MG
Aliment Pharmacol Ther; 2018 Jul; 48(2):196-205. PubMed ID: 29869804
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and Outcome of Extranodal Primary Intestinal Lymphoma in Inflammatory Bowel Disease: An ECCO CONFER Case Series.
Phillips F; Verstockt B; Ribaldone DG; Guerra I; Teich N; Katsanos K; Filip R; Molner T; Karmiris K;
J Crohns Colitis; 2022 Mar; 16(3):500-505. PubMed ID: 34508639
[TBL] [Abstract][Full Text] [Related]
18. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.
Lemaitre M; Kirchgesner J; Rudnichi A; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
JAMA; 2017 Nov; 318(17):1679-1686. PubMed ID: 29114832
[TBL] [Abstract][Full Text] [Related]
19. Increased risk of pneumonia among patients with inflammatory bowel disease.
Long MD; Martin C; Sandler RS; Kappelman MD
Am J Gastroenterol; 2013 Feb; 108(2):240-8. PubMed ID: 23295276
[TBL] [Abstract][Full Text] [Related]
20. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
